To clearly determine whether LRP16 expression could be extended to NF-κB activity in clinical samples, human gastric carcinoma specimens were selected, instead of hormone related cancers, in order to exclude the possible competitive interaction interference of LRP16 with other transcription factors, such as ERα and AR. The gene discussed is ESR1; the disease is cancer.